Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Evoke Pharma (EVOK) EBIT (2020 - 2025)

Historic EBIT for Evoke Pharma (EVOK) over the last 6 years, with Q3 2025 value amounting to -$1.1 million.

  • Evoke Pharma's EBIT rose 1150.92% to -$1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.2 million, marking a year-over-year increase of 1197.58%. This contributed to the annual value of -$5.2 million for FY2024, which is 2996.62% up from last year.
  • Per Evoke Pharma's latest filing, its EBIT stood at -$1.1 million for Q3 2025, which was up 1150.92% from -$1.6 million recorded in Q2 2025.
  • In the past 5 years, Evoke Pharma's EBIT ranged from a high of -$1.1 million in Q3 2025 and a low of -$2.6 million during Q1 2021
  • Moreover, its 5-year median value for EBIT was -$1.7 million (2022), whereas its average is -$1.7 million.
  • As far as peak fluctuations go, Evoke Pharma's EBIT surged by 6885.85% in 2021, and later plummeted by 2740.28% in 2025.
  • Evoke Pharma's EBIT (Quarter) stood at -$1.5 million in 2021, then fell by 10.5% to -$1.7 million in 2022, then fell by 10.42% to -$1.9 million in 2023, then surged by 36.77% to -$1.2 million in 2024, then grew by 4.69% to -$1.1 million in 2025.
  • Its last three reported values are -$1.1 million in Q3 2025, -$1.6 million for Q2 2025, and -$1.3 million during Q1 2025.